Merck ponders next step for troubled heart drug  MARILYNN
MARCHIONE AP Chief Medical Writer Published:    The drug,
vorapaxar, (vor-uh-PACKS-ahr) did lower the risk of these
problems. But it also raised the risk of major bleeding,
including dangerous bleeding in the head, which largely canceled
out the drug's benefit.  The study involved more than 26,000
patients in 32 countries.